


Thymectacin

Chemical Properties

CAS No. :	232925-18-7
Formula:	C ₂₁ H ₂₅ BrN ₃ O ₉ P
Molecular Weight:	574.32
Storage:	Keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Thymectacin (NB 1011) is a selective thymidine synthase (TS) inhibitor with anticancer activity for the study of colon cancer and solid tumors.
Targets(IC50)	Others,DNA/RNA Synthesis
In vitro	The main clinical candidate, Thymectacin, showed only moderate activity in vitro, with EC ₅₀ values ranging from 79-245 μM in our assay. However, relatively minor structural adjustments resulted in a significant increase in potency.MDA-MB 231 EC ₅₀ =79 μM, HT 115 EC ₅₀ =245 μM, and PC-3 EC ₅₀ =155 μM. [1]

Solubility Information

Solubility	DMSO: 80 mg/mL(139.30 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.48 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7412 mL	8.7059 mL	17.4119 mL
5 mM	0.3482 mL	1.7412 mL	3.4824 mL
10 mM	0.1741 mL	0.8706 mL	1.7412 mL
50 mM	0.0348 mL	0.1741 mL	0.3482 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

McGuigan C, et al. Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin.

Bioorg Med Chem. 2005 May 2;13(9):3219-27.

Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist.

2006 Oct;11(9):1018-24.

McGuigan C, Thiery JC, Daverio F, Jiang WG, Davies G, Mason M. Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. Bioorg Med Chem. 2005 May 2;13(9):3219-27. PubMed PMID: 15809157.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481